Bile proteomics for differentiation of malignant from benign biliary strictures: A pilot study

Gastroenterology Report

Volumn 3, Issue 2, 2015, Pages 136-143

  Navaneethan, Udayakumar ^a   Lourdusamy, Vennisvasanth ^a   Venkatesh, Preethi G K ^a   Willard, Belinda ^a   Sanaka, Madhusudhan R ^a   Parsi, Mansour A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bile; Cholangiocarcinoma; Pancreatic cancer; Proteomics

Indexed keywords

EID: 84955477709     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gou066     Document Type: Article

References (36)

1. Friman S. Cholangiocarcinoma: current treatment options. Scand J Surg 2011;100:30-4.
2. Saif MW. Pancreatic neoplasm in 2011: an update. JOP 2011;12:316-21.
3. Weilert F, Bhat YM, Binmoeller KF et al. EUS-FNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a prospective, single-blind, comparative study. Gastrointest Endosc 2014;80: 97-104.
4. Baron TH, Harewood GC, Rumalla A et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004;2:214-9.
5. Parsi MA, Li A, Li CP et al. DNA methylation alterations in en-doscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease. Clin Gastroenterol Hepatol 2008;6:1270-8.
6. Trikudanathan G, Navaneethan U, Njei B et al. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014;79:783-9.
7. Smoczynski M, Jablonska A, Matyskiel A et al. Routine brush cytology and fluorescence in situ hybridization for assessment of pancreatobiliary strictures. Gastrointest Endosc 2012;75:65-73.
8. Moreno Luna LE, Kipp B, Halling KC et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006;131:1064-72.
9. Navaneethan U, Njei B, Venkatesh PG et al. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014;79:943-50.e3.
10. Farina A, Dumonceau JM, Delhaye M et al. A step further in the analysis of human bile proteome. J Proteome Res 2011;10:2047-63.
11. Lukic N, Visentin R, Delhaye M et al. An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis. Biochim Biophys Acta 2014;1844:1026-33.
12. Barbhuiya MA, Sahasrabuddhe NA, Pinto SM et al. Comprehensive proteomic analysis of human bile. Proteomics 2011;11:4443-53.
13. Farid SG, Craven RA, Peng J et al. Shotgun proteomics of human bile in hilar cholangiocarcinoma. Proteomics 2011; 11:2134-8.
14. Lankisch TO, Metzger J, Negm AA et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 2011;53: 875-84.
15. Farina A, Dumonceau JM, Frossard JL et al. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. J Proteome Res 2009;8:159-69.
16. Keller A, Nesvizhskii AI, Kolker E et al. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002; 74:5383-92.
17. Nesvizhskii AI, Keller A, Kolker E et al. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003;75:4646-58.
18. Liu H, Sadygov RG and Yates JR 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Analytical chemistry 2004;76:4193-201.
19. Zhang Y, Wen Z, Washburn MP et al. Refinements to Label Free Proteome Quantitation: How to Deal with Peptides Shared by Multiple Proteins. Anal. Chem 2010;82:2272-81.
20. Gokce E, Shuford CM, Franck WL et al. Evaluation of normali-zation methods on gelc-ms/ms label-free spectral counting data to correct for variation during proteomic workflows. J Am Soc Mass Spectrom 2011;22:2199-208.
21. Ballehaninna UK and Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 2012;3:105-19.
22. Parikh DA, Durbin-Johnson B and Urayama S. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocar-cinoma in an endoscopic ultrasound referral population. J Gastrointest Cancer 2014;45:74-9.
23. Navaneethan U, Gutierrez NG, Jegadeesan R et al. Vascular endothelial growth factor levels in bile distinguishes pancreatic cancer from other etiologies of biliary stricture: a pilot study. Dig Dis Sci 2013;58:2986-92.
24. Navaneethan U, Gutierrez NG, Venkatesh PG et al. Lipidomic profiling of bile in distinguishing benign from malignant biliary strictures: a single-blinded pilot study. Am J Gastroenterol 2014;109:895-902.
25. Navaneethan U, Parsi MA, Gutierrez NG et al. Volatile organic compounds in bile can diagnose malignant biliary strictures in the setting of pancreatic cancer: a preliminary observation. Gastrointest Endosc 2014 Jun 11, doi: 10.1016/j.gie.2014.04.016.
26. Wulfkuhle JD, Liotta LA and Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003;3: 267-75.
27. Shi Y, Deng X, Zhan Q et al. A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of cholangiocarcinoma. J Gastrointest Surg 2013;17:1584-91.
28. Zabron AA, Horneffer-van der Sluis VM, Wadsworth CA et al. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease. Am J Gastroenterol 2011;106:1711-7.
29. Tyson GL and El-Serag HB. Risk factors for cholangiocarci-noma. Hepatology 2011;54:173-84.
30. Liu R, Cox K, Guthery SL et al. Cholangiocarcinoma and high-grade dysplasia in young patients with primary sclerosing cholangitis. Dig Dis Sci 2014;59:2320-4.
31. Burak K, Angulo P, Pasha TM et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523-6.
32. Dubeykovskaya Z, Dubeykovskiy A, Solal-Cohen J et al. Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines. J Biol Chem 2009;284:3650-62.
33. Jiang P, Yu G, Zhang Y et al. Promoter hypermethylation and downregulation of trefoil factor 2 in human gastric cancer. Oncol Lett 2014;7:1525-31.
34. Zhang J, Zhang DL, Jiao XL et al. S100A4 regulates migration and invasion in hepatocellular carcinoma HepG2 cells via NF-jB-dependent MMP-9 signal. Eur Rev Med Pharmacol Sci 2013;17:2372-82.
35. Kaur J, Matta A, Kak I et al. S100A7 overexpression is a predic-tive marker for high risk of malignant transformation in oral dysplasia. Int J Cancer 2014;134:1379-88.
36. Xu C, Chen H, Wang X et al. S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling. J Biol Chem 2014;289:827-37.